Pharmacokinetic interference of doxorubicin with tolbutamide due to reduced metabolic clearance with increased serum unbound fraction in rats

• Published in: Biopharmaceutics & drug disposition 2019-07, Vol.40 (7), p.225-233
• Main Authors: Fukuno, Shuhei, Nagai, Katsuhito, Yamamoto, Kohei, Tanimura, Takehiro, Nabe, Takeshi, Konishi, Hiroki
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics, Antineoplastic - pharmacology; Aryl Hydrocarbon Hydroxylases - metabolism; Cytochrome P450 Family 2 - metabolism; Doxorubicin; Doxorubicin - pharmacology; Drug Interactions; Enzymatic activity; Enzyme kinetics; Exposure; hepatic CYP2C; Hydroxylation; Hydroxylation - drug effects; Hypoglycemic Agents - blood; Hypoglycemic Agents - pharmacokinetics; Liver; Male; Metabolic Clearance Rate - drug effects; Metabolism; Microsomes; Microsomes, Liver - metabolism; Pharmacokinetics; protein binding; Rats, Sprague-Dawley; Serum Albumin - metabolism; Steroid 16-alpha-Hydroxylase - metabolism; Tolbutamide; Tolbutamide - blood; Tolbutamide - pharmacokinetics
• ISSN: 0142-2782; 1099-081X
• DOI: 10.1002/bdd.2195

The study examined the effect of doxorubicin (DOX) on the hepatic expression of CYP2C and its activity for metabolizing tolbutamide (TB), a specific CYP2C substrate, in rats and whether the pharmacokinetics of tolbutamide were altered by doxorubicin exposure. The expression level of hepatic CYP2C11 was depressed 1 day after doxorubicin administration (day 1), and this effect on CYP2C11 was augmented on day 4. However, the expression level of hepatic CYP2C6 remained unchanged. The activity of tolbutamide 4‐hydroxylation in hepatic microsomes was decreased with time following doxorubicin administration. Regarding the enzyme kinetic parameters for tolbutamide 4‐hydroxylation on day 4, the maximum velocity (Vmax) was significantly lower in the DOX group than that in the control group, while the Michaelis constant (Km) was unaffected. On pharmacokinetic examination, the total clearance (CLtot) of tolbutamide on day 4 was increased, despite the decreased metabolic capacity. On the other hand, the serum unbound fraction (fu) of tolbutamide was elevated with a reduced serum albumin concentration in the DOX group. Contrary to CLtot, CLtot/fu, a parameter approximated to the hepatic intrinsic clearance of unbound tolbutamide, was estimated to be significantly reduced in the DOX group. These findings indicate that the metabolic capacity of CYP2C11 in the liver is depressed time‐dependently by down‐regulation after doxorubicin exposure in rats, and that the decreased enzyme activity of TB 4‐hydroxylation in hepatic microsomes reflects the pharmacokinetic change of unbound tolbutamide, not total tolbutamide, in serum.